Mettke F, et al. - Here, the researchers examined the hepatocellular carcinoma (HCC) incidence in cirrhotic hepatitis C virus (HCV) patients who cleared HCV with direct-acting antivirals vs untreated controls. Among patients with liver cirrhosis, IFN-free direct-acting antiviral therapy of chronic hepatitis C did not alter the short-term risk for HCC. After more than 1.5 years of follow-up, a reduced HCC incidence could become evident.